These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21531625)

  • 1. B cell-directed therapies in type 1 diabetes.
    Mariño E; Silveira PA; Stolp J; Grey ST
    Trends Immunol; 2011 Jun; 32(6):287-94. PubMed ID: 21531625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice.
    Falcone M; Lee J; Patstone G; Yeung B; Sarvetnick N
    J Immunol; 1998 Aug; 161(3):1163-8. PubMed ID: 9686575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes.
    Silveira PA; Grey ST
    Trends Endocrinol Metab; 2006; 17(4):128-35. PubMed ID: 16580840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective destruction of mouse islet beta cells by human T lymphocytes in a newly-established humanized type 1 diabetic model.
    Zhao Y; Guo C; Hwang D; Lin B; Dingeldein M; Mihailescu D; Sam S; Sidhwani S; Zhang Y; Jain S; Skidgel RA; Prabhakar BS; Mazzone T; Holterman MJ
    Biochem Biophys Res Commun; 2010 Sep; 399(4):629-36. PubMed ID: 20691153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of insulitis and diabetes in B cell-deficient NOD mice.
    Yang M; Charlton B; Gautam AM
    J Autoimmun; 1997 Jun; 10(3):257-60. PubMed ID: 9218752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Of mice and men: use of animal models to identify possible interventions for the prevention of autoimmune type 1 diabetes in humans.
    Serreze DV; Chen YG
    Trends Immunol; 2005 Nov; 26(11):603-7. PubMed ID: 16140038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To B or not to B--pathogenic and regulatory B cells in autoimmune diabetes.
    Wong FS; Hu C; Xiang Y; Wen L
    Curr Opin Immunol; 2010 Dec; 22(6):723-31. PubMed ID: 21050736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3 antibody treatment stimulates the functional capability of regulatory T cells.
    Chatenoud L
    Novartis Found Symp; 2003; 252():279-86; discussion 286-90. PubMed ID: 14609225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice.
    Piccirillo CA; Tritt M; Sgouroudis E; Albanese A; Pyzik M; Hay V
    Ann N Y Acad Sci; 2005 Jun; 1051():72-87. PubMed ID: 16126946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice.
    Noorchashm H; Lieu YK; Noorchashm N; Rostami SY; Greeley SA; Schlachterman A; Song HK; Noto LE; Jevnikar AM; Barker CF; Naji A
    J Immunol; 1999 Jul; 163(2):743-50. PubMed ID: 10395666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors.
    Silveira PA; Johnson E; Chapman HD; Bui T; Tisch RM; Serreze DV
    Eur J Immunol; 2002 Dec; 32(12):3657-66. PubMed ID: 12516557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell therapy is β-tested: Rituximab puts a pause on β-cell destruction.
    Clynes R
    Islets; 2010; 2(2):130-2. PubMed ID: 21099307
    [No Abstract]   [Full Text] [Related]  

  • 14. "Humanized" HLA transgenic NOD mice to identify pancreatic beta cell autoantigens of potential clinical relevance to type 1 diabetes.
    Serreze DV; Marron MP; Dilorenzo TP
    Ann N Y Acad Sci; 2007 Apr; 1103():103-11. PubMed ID: 17376821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cells and type 1 diabetes ...in mice and men.
    Hinman RM; Smith MJ; Cambier JC
    Immunol Lett; 2014 Aug; 160(2):128-32. PubMed ID: 24472603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice.
    DiLorenzo TP; Serreze DV
    Immunol Rev; 2005 Apr; 204():250-63. PubMed ID: 15790363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging roles for B lymphocytes in Type 1 diabetes.
    Cox SL; Silveira PA
    Expert Rev Clin Immunol; 2009 May; 5(3):311-24. PubMed ID: 20477009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of interferon alpha in initiation of type I diabetes in the NOD mouse.
    Li Q; McDevitt HO
    Clin Immunol; 2011 Jul; 140(1):3-7. PubMed ID: 21592863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell immunotherapy in autoimmunity--2010 update.
    Chan AC
    Mol Immunol; 2011 Jun; 48(11):1344-7. PubMed ID: 21194752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging mice to men: using HLA transgenic mice to enhance the future prediction and prevention of autoimmune type 1 diabetes in humans.
    Serreze DV; Niens M; Kulik J; Dilorenzo TP
    Methods Mol Biol; 2010; 602():119-34. PubMed ID: 20012396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.